The James Buchanan Brady Urological Institute
 William B. Isaacs, Ph.D. William B. Isaacs, Ph.D.
William Thomas Gerrard, Mario Anthony Duhon and Jennifer and John Chalsty Professor of Urology
Professor of Oncology

Johns Hopkins University School of Medicine

Email:wisaacs@jhmi.edu
Free Access to abstracts at PubMed

ARTICLES PUBLISHED IN PROFESSIONAL JOURNALS
1. A Genome-Wide Survey over the ChIP-On-Chip Identified Androgen Receptor-Binding Genomic Regions Identifies a Novel Prostate Cancer Susceptibility Locus at 12q13.13. 
Feng J, Sun J, Kim ST, Lu Y, Wang Z, Zhang Z, Gronberg H, Isaacs WB, Zheng SL, Xu J.
Cancer Epidemiol Biomarkers Prev. 2011 Oct 18. [Epub ahead of print]
2. PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients.
Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM.
Clin Cancer Res. 2011 Oct 15;17(20):6563-73. Epub 2011 Aug 30.
3. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study.
Cheng Y, Liu W, Kim ST, Sun J, Lu L, Sun J, Zheng SL, Isaacs WB, Xu J.
Cancer Genet. 2011 Jul;204(7):375-81. doi: 10.1016/j.cancergen.2011.05.002.
4. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk.
Jin G, Sun J, Isaacs SD, Wiley KE, Kim ST, Chu LW, Zhang Z, Zhao H, Zheng SL, Isaacs WB, Xu J.
Carcinogenesis. 2011 Nov;32(11):1655-9. Epub 2011 Aug 19.
5. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.
Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, Ostrander EA, Feng Z, Grönberg H, Stanford JL.
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1928-36. Epub 2011 Aug 16.
6. Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration.
Sutcliffe S, Nevin RL, Pakpahan R, Elliott DJ, Cole SR, De Marzo AM, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Zenilman JM, Cersovsky SB, Platz EA.
Br J Cancer. 2011 Aug 23;105(5):602-5. doi: 10.1038/bjc.2011.271. Epub 2011 Jul 26.
7. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG.
Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, Wiklund F, Emanuelsson M, Grönberg H, Wiley KE, Isaacs SD, Walsh PC, Helfand BT, Kan D, Catalona WJ, Stanford JL, Fitzgerald LM, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Whittemore AS, Oakley-Girvan I, Hsieh CL, Powell I, Bailey-Wilson JE, Cropp CD, Simpson C, Carpten JD, Seminara D, Zheng SL, Xu J, Giles GG, Severi G, Hopper JL, English DR, Foulkes WD, Maehle L, Moller P, Badzioch MD, Edwards S, Guy M, Eeles R, Easton D, Isaacs WB; International Consortium for Prostate Cancer Genetics.
Prostate. 2011 Jul 11. doi: 10.1002/pros.21443. [Epub ahead of print]
8. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.
Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA, Netto GJ.
Mod Pathol. 2011 Nov;24(11):1511-20. doi: 10.1038/modpathol.2011.111. Epub 2011 Jul 8.
9. Genome-wide association study identifies new prostate cancer susceptibility loci.
Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, Stevens VL, Chen C, Mondul AM, Travis RC, Stram DO, Eeles RA, Easton DF, Giles G, Hopper JL, Neal DE, Hamdy FC, Donovan JL, Muir K, Al Olama AA, Kote-Jarai Z, Guy M, Severi G, Grönberg H, Isaacs WB, Karlsson R, Wiklund F, Xu J, Allen NE, Andriole GL, Barricarte A, Boeing H, Bueno-de-Mesquita HB, Crawford ED, Diver WR, Gonzalez CA, Gaziano JM, Giovannucci EL, Johansson M, Le Marchand L, Ma J, Sieri S, Stattin P, Stampfer MJ, Tjonneland A, Vineis P, Virtamo J, Vogel U, Weinstein SJ, Yeager M, Thun MJ, Kolonel LN, Henderson BE, Albanes D, Hayes RB, Feigelson HS, Riboli E, Hunter DJ, Chanock SJ, Haiman CA, Kraft P.
Hum Mol Genet. 2011 Oct 1;20(19):3867-75. Epub 2011 Jul 8.
10. Association of prostate cancer risk with snps in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses.
Lu Y, Sun J, Kader AK, Kim ST, Kim JW, Liu W, Sun J, Lu D, Feng J, Zhu Y, Jin T, Zhang Z, Dimitrov L, Lowey J, Campbell K, Suh E, Duggan D, Carpten J, Trent JM, Gronberg H, Zheng SL, Isaacs WB, Xu J.
Prostate. 2011 Jun 10. doi: 10.1002/pros.21439. [Epub ahead of print]
11. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans.
Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, Diver WR, Witte JS, Chanock SJ, Kolb S, Signorello LB, Yamamura Y, Neslund-Dudas C, Thun MJ, Murphy A, Casey G, Sheng X, Wan P, Pooler LC, Monroe KR, Waters KM, Le Marchand L, Kolonel LN, Stram DO, Henderson BE.
PLoS Genet. 2011 May;7(5):e1001387. Epub 2011 May 26.
12. Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility.
Xie CC, Lu L, Sun J, Zheng SL, Isaacs WB, Gronberg H, Xu J.
J Hum Genet. 2011 Jul;56(7):496-502. doi: 10.1038/jhg.2011.48. Epub 2011 Jun 2.
13. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21.
Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, Diver WR, Witte JS, Hsing AW, Nemesure B, Rebbeck TR, Cooney KA, Xu J, Kibel AS, Hu JJ, John EM, Gueye SM, Watya S, Signorello LB, Hayes RB, Wang Z, Yeboah E, Tettey Y, Cai Q, Kolb S, Ostrander EA, Zeigler-Johnson C, Yamamura Y, Neslund-Dudas C, Haslag-Minoff J, Wu W, Thomas V, Allen GO, Murphy A, Chang BL, Zheng SL, Leske MC, Wu SY, Ray AM, Hennis AJ, Thun MJ, Carpten J, Casey G, Carter EN, Duarte ER, Xia LY, Sheng X, Wan P, Pooler LC, Cheng I, Monroe KR, Schumacher F, Le Marchand L, Kolonel LN, Chanock SJ, Berg DV, Stram DO, Henderson BE.
Nat Genet. 2011 Jun;43(6):570-3. Epub 2011 May 22.
14. National Cancer Institute Prostate Cancer Genetics Workshop.
Catalona WJ, Bailey-Wilson JE, Camp NJ, Chanock SJ, Cooney KA, Easton DF, Eeles RA, FitzGerald LM, Freedman ML, Gudmundsson J, Kittles RA, Margulies EH, McGuire BB, Ostrander EA, Rebbeck TR, Stanford JL, Thibodeau SN, Witte JS, Isaacs WB.
Cancer Res. 2011 May 15;71(10):3442-6. Epub 2011 May 10.
15. Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer.
Jin G, Sun J, Liu W, Zhang Z, Chu LW, Kim ST, Sun J, Feng J, Duggan D, Carpten JD, Wiklund F, Grönberg H, Isaacs WB, Zheng SL, Xu J.
Carcinogenesis. 2011 Jul;32(7):1057-62. Epub 2011 May 5.
16. Functional annotation of risk loci identified through genome-wide association studies for prostate cancer.
Lu Y, Zhang Z, Yu H, Zheng SL, Isaacs WB, Xu J, Sun J.
Prostate. 2011 Jun 15;71(9):955-63. doi: 10.1002/pros.21311. Epub 2010 Dec 6.
17. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer.
Chung CC, Ciampa J, Yeager M, Jacobs KB, Berndt SI, Hayes RB, Gonzalez-Bosquet J, Kraft P, Wacholder S, Orr N, Yu K, Hutchinson A, Boland J, Chen Q, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Key TJ, Kaaks R, Isaacs WB, Isaacs SD, Grönberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Njolstad I, Gerhard DS, Tucker M, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chatterjee N, Chanock SJ.
Hum Mol Genet. 2011 Jul 15;20(14):2869-78. Epub 2011 Apr 29.
18. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities.
Hu R, Isaacs WB, Luo J.
Prostate. 2011 Nov;71(15):1656-67. doi: 10.1002/pros.21382. Epub 2011 Mar 28.
19. High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S).
Wilson BA, Wang H, Nacev BA, Mease RC, Liu JO, Pomper MG, Isaacs WB.
Mol Cancer Ther. 2011 May;10(5):825-38. Epub 2011 Mar 25.
20. Prostate cancer-derived angiogenin stimulates the invasion of prostate fibroblasts.
Jones ML, Ewing CM, Isaacs WB, Getzenberg RH.
J Cell Mol Med. 2011 Feb 25. doi: 10.1111/j.1582-4934.2011.01283.x. [Epub ahead of print]
21. Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.
Ahn J, Kibel AS, Park JY, Rebbeck TR, Rennert H, Stanford JL, Ostrander EA, Chanock S, Wang MH, Mittal RD, Isaacs WB, Platz EA, Hayes RB.
Clin Cancer Res. 2011 Mar 1;17(5):1075-81. Epub 2011 Feb 22.
22. Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study.
Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, D'Amato M, Adolfsson J, Grönberg H.
Eur Urol. 2011 Jul;60(1):21-8. Epub 2011 Jan 18.
23. Functional annotation of risk loci identified through genome-wide association studies for prostate cancer.
Lu Y, Zhang Z, Yu H, Zheng SL, Isaacs WB, Xu J, Sun J.
Prostate. 2010 Dec 6. [Epub ahead of print]
24. XMRV: a new virus in prostate cancer?
Aloia AL, Sfanos KS, Isaacs WB, Zheng Q, Maldarelli F, De Marzo AM, Rein A.
Cancer Res. 2010 Dec 15;70(24):10028-33. Epub 2010 Oct 21.
25. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status.
Fujita K, Ewing CM, Isaacs WB, Pavlovich CP.
Int J Cancer. 2011 Jul 15;129(2):424-32. doi: 10.1002/ijc.25705. Epub 2010 Nov 16.
26. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.
Sun J, Kader AK, Hsu FC, Kim ST, Zhu Y, Turner AR, Jin T, Zhang Z, Adolfsson J, Wiklund F, Zheng SL, Isaacs WB, Grönberg H, Xu J.
Prostate. 2011 Mar 1;71(4):421-30. doi: 10.1002/pros.21256. Epub 2010 Sep 28.
27. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.
Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S.
Nat Genet. 2010 Aug;42(8):668-75. Epub 2010 Jul 4.
28. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation.
Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, Isaacs WB, Xu J, Sun J.
Prostate. 2010 Dec 1;70(16):1729-38.
29. Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies.
Elliott KS, Zeggini E, McCarthy MI, Gudmundsson J, Sulem P, Stacey SN, Thorlacius S, Amundadottir L, Grönberg H, Xu J, Gaborieau V, Eeles RA, Neal DE, Donovan JL, Hamdy FC, Muir K, Hwang SJ, Spitz MR, Zanke B, Carvajal-Carmona L, Brown KM; Australian Melanoma Family Study Investigators, Hayward NK, Macgregor S, Tomlinson IP, Lemire M, Amos CI, Murabito JM, Isaacs WB, Easton DF, Brennan P; PanScan Consortium, Barkardottir RB, Gudbjartsson DF, Rafnar T, Hunter DJ, Chanock SJ, Stefansson K, Ioannidis JP.
PLoS One. 2010 May 28;5(5):e10858.
30. Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2.
Prokunina-Olsson L, Fu YP, Tang W, Jacobs KB, Hayes RB, Kraft P, Berndt SI, Wacholder S, Yu K, Hutchinson A, Spencer Feigelson H, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis R, Kaaks R, Isaacs WB, Isaacs SD, Grönberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Kumle M, Tucker M, Hoover RN, Fraumeni JF Jr, Hunter DJ, Thomas G, Chatterjee N, Chanock SJ, Yeager M.
Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1349-55. Epub 2010 Apr 20.
31. Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses.
Christensen GB, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Lange EM, Cooney KA, Tammela TL, Schleutker J, Paiss T, Maier C, Grönberg H, Wiklund F, Emanuelsson M, Farnham JM, Cannon-Albright LA, Camp NJ; International Consortium for Prostate Cancer Genetics.
Prostate. 2010 May 15;70(7):735-44.
32. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.
Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F, Sun J, Kader AK, Li G, Purcell LD, Kim ST, Hsu FC, Stattin P, Hugosson J, Adolfsson J, Walsh PC, Trent JM, Duggan D, Carpten J, Grönberg H, Isaacs WB.
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2136-40. Epub 2010 Jan 11.
33. Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma.
Lubahn J, Berndt SI, Jin CH, Klim A, Luly J, Wu WS, Isaacs S, Wiley K, Isaacs WB, Suarez BK, Hayes RB, Kibel AS.
Prostate. 2010 May 1;70(6):646-53.
34. Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.
Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB, Pavlovich CP.
Prostate. 2010 Apr 1;70(5):473-81.
35. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men.
Zheng SL, Hsing AW, Sun J, Chu LW, Yu K, Li G, Gao Z, Kim ST, Isaacs WB, Shen MC, Gao YT, Hoover RN, Xu J.
Prostate. 2010 Mar 1;70(4):425-32.
36. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer.
Brown DA, Lindmark F, Stattin P, Bälter K, Adami HO, Zheng SL, Xu J, Isaacs WB, Grönberg H, Breit SN, Wiklund FE.
Clin Cancer Res. 2009 Nov 1;15(21):6658-64. Epub 2009 Oct 20.
37. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.
Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, A Platz E, Meeker AK, Demarzo AM, Epstein JI, Netto GJ.
Mod Pathol. 2009 Nov;22(11):1415-22. Epub 2009 Sep 4.
38. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.
Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG.
Prostate. 2009 Nov 1;69(15):1694-703.
39. Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?
Loeb S, Helfand BT, Kan D, Isaacs WB, Catalona WJ.
BJU Int. 2009 Nov;104(9):1200-3. Epub 2009 Jul 20.
40. Estimation of absolute risk for prostate cancer using genetic markers and family history.
Xu J, Sun J, Kader AK, Lindström S, Wiklund F, Hsu FC, Johansson JE, Zheng SL, Thomas G, Hayes RB, Kraft P, Hunter DJ, Chanock SJ, Isaacs WB, Grönberg H.
Prostate. 2009 Oct 1;69(14):1565-72.
41. Fine-mapping and family-based association analyses of prostate cancer risk variants at Xp11.
Lu L, Sun J, Isaacs SD, Wiley KE, Smith S, Pruett K, Zhu Y, Zhang Z, Wiklund F, Grönberg H, Walsh PC, Chang BL, Zheng SL, Isaacs WB, Xu J.
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2132-6. Epub 2009 Jun 23.
42. Prostate cancer risk associated loci in African Americans.
Xu J, Kibel AS, Hu JJ, Turner AR, Pruett K, Zheng SL, Sun J, Isaacs SD, Wiley KE, Kim ST, Hsu FC, Wu W, Torti FM, Walsh PC, Chang BL, Isaacs WB.
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2145-9. Epub 2009 Jun 23.
43. Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level.
Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, Metter EJ.
J Urol. 2009 Jul;182(1):101-4; discussion 105. Epub 2009 May 17.
44. Established prostate cancer susceptibility variants are not associated with disease outcome.
Wiklund FE, Adami HO, Zheng SL, Stattin P, Isaacs WB, Grönberg H, Xu J.
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1659-62.
45. Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology.
Fujita K, Pavlovich CP, Netto GJ, Konishi Y, Isaacs WB, Ali S, De Marzo A, Meeker AK.
Hum Pathol. 2009 Jul;40(7):924-33. Epub 2009 Apr 14.
46. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS.
Nat Med. 2009 May;15(5):559-65. Epub 2009 Apr 12. Erratum in: Nat Med. 2009 Jul;15(7):819.
47. A novel prostate cancer susceptibility locus at 19q13.
Hsu FC, Sun J, Wiklund F, Isaacs SD, Wiley KE, Purcell LD, Gao Z, Stattin P, Zhu Y, Kim ST, Zhang Z, Liu W, Chang BL, Walsh PC, Duggan D, Carpten JD, Isaacs WB, Grönberg H, Xu J, Zheng SL.
Cancer Res. 2009 Apr 1;69(7):2720-3. Epub 2009 Mar 24.
48. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II.
Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, De Marzo AM, Isaacs WB, Drake CG, Shugart YY, Platz EA.
Prostate. 2009 Jun 1;69(8):874-85.
49. Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer.
Liu W, Sun J, Li G, Zhu Y, Zhang S, Kim ST, Sun J, Wiklund F, Wiley K, Isaacs SD, Stattin P, Xu J, Duggan D, Carpten JD, Isaacs WB, Grönberg H, Zheng SL, Chang BL.
Cancer Res. 2009 Mar 15;69(6):2176-9. Epub 2009 Mar 3.
50. Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer.
Sfanos KS, Wilson BA, De Marzo AM, Isaacs WB.
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3443-8. Epub 2009 Feb 6.
51. Genetic variants and family history predict prostate cancer similar to prostate-specific antigen.
Zheng SL, Sun J, Wiklund F, Gao Z, Stattin P, Purcell LD, Adami HO, Hsu FC, Zhu Y, Adolfsson J, Johansson JE, Turner AR, Adams TS, Liu W, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H.
Clin Cancer Res. 2009 Feb 1;15(3):1105-11.
52. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk.
Chang BL, Cramer SD, Wiklund F, Isaacs SD, Stevens VL, Sun J, Smith S, Pruett K, Romero LM, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC, Turner AR, Adolfsson J, Liu W, Kim JW, Duggan D, Carpten J, Zheng SL, Rodriguez C, Isaacs WB, Grönberg H, Xu J.
Hum Mol Genet. 2009 Apr 1;18(7):1368-75. Epub 2009 Jan 19.
53. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells.
Parsons JK, Saria EA, Nakayama M, Vessella RL, Sawyers CL, Isaacs WB, Faith DA, Bova GS, Samathanam CA, Mitchell R, De Marzo AM.
Prostate. 2009 Apr 1;69(5):559-69.
54. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.
Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J.
Cancer Res. 2009 Jan 1;69(1):16-22.
55. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
Wiklund F, Zheng SL, Sun J, Adami HO, Lilja H, Hsu FC, Stattin P, Adolfsson J, Cramer SD, Duggan D, Carpten JD, Chang BL, Isaacs WB, Grönberg H, Xu J.
Prostate. 2009 Mar 1;69(4):419-27.
56. Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.
Cheng Y, Kim JW, Liu W, Dunn TA, Luo J, Loza MJ, Kim ST, Zheng SL, Xu J, Isaacs WB, Chang BL.
Prostate. 2009 Feb 15;69(3):327-35.
57. Genetic and epigenetic inactivation of LPL gene in human prostate cancer.
Kim JW, Cheng Y, Liu W, Li T, Yegnasubramanian S, Zheng SL, Xu J, Isaacs WB, Chang BL.
Int J Cancer. 2009 Feb 1;124(3):734-8.
58. Endoglin (CD105) as a urinary and serum marker of prostate cancer.
Fujita K, Ewing CM, Chan DY, Mangold LA, Partin AW, Isaacs WB, Pavlovich CP.
Int J Cancer. 2009 Feb 1;124(3):664-9.
59. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.
Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG.
Cancer Res. 2008 Nov 1;68(21):8954-67.
60. Genome-wide expression analysis of recently processed formalin-fixed paraffin embedded human prostate tissues.
Dunn TA, Fedor H, Isaacs WB, De Marzo AM, Luo J.
Prostate. 2009 Feb 1;69(2):214-8.
61. Family-based samples can play an important role in genetic association studies.
Lange EM, Sun J, Lange LA, Zheng SL, Duggan D, Carpten JD, Gronberg H, Isaacs WB, Xu J, Chang BL.
Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2208-14.
62. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12.
Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD, Gao Z, Hsu FC, Kim ST, Liu W, Zhu Y, Stattin P, Adami HO, Wiley KE, Dimitrov L, Sun J, Li T, Turner AR, Adams TS, Adolfsson J, Johansson JE, Lowey J, Trock BJ, Partin AW, Walsh PC, Trent JM, Duggan D, Carpten J, Chang BL, Grönberg H, Isaacs WB, Xu J.
Nat Genet. 2008 Oct;40(10):1153-5. Epub 2008 Aug 31.
63. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.
Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Ewing CM, Dalrymple S, Turner AR, Sun J, Isaacs JT, Chang BL, Zheng SL, Isaacs WB, Xu J.
Neoplasia. 2008 Aug;10(8):897-907.
64. An evaluation of PCR primer sets used for detection of Propionibacterium acnes in prostate tissue samples.
Sfanos KS, Isaacs WB.
Prostate. 2008 Oct 1;68(14):1492-5.
65. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer.
Tischkowitz MD, Yilmaz A, Chen LQ, Karyadi DM, Novak D, Kirchhoff T, Hamel N, Tavtigian SV, Kolb S, Bismar TA, Aloyz R, Nelson PS, Hood L, Narod SA, White KA, Ostrander EA, Isaacs WB, Offit K, Cooney KA, Stanford JL, Foulkes WD.
Cancer Lett. 2008 Oct 18;270(1):173-80. Epub 2008 Jun 20.
66. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.
Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM.
Mod Pathol. 2008 Sep;21(9):1156-67. Epub 2008 Jun 20.
67. alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling.
Inge LJ, Rajasekaran SA, Wolle D, Barwe SP, Ryazantsev S, Ewing CM, Isaacs WB, Rajasekaran AK.
Mol Cancer Ther. 2008 Jun;7(6):1386-97.
68. GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.
Wei S, Dunn TA, Isaacs WB, De Marzo AM, Luo J.
Prostate. 2008 Sep 15;68(13):1387-95.
69. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing.
Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG.
Clin Cancer Res. 2008 Jun 1;14(11):3254-61.
70. A multigenic approach to evaluating prostate cancer risk in a systematic replication study.
Hsu FC, Lindström S, Sun J, Wiklund F, Chen SH, Adami HO, Turner AR, Liu W, Bälter K, Kim JW, Stattin P, Chang BL, Isaacs WB, Xu J, Grönberg H, Zheng SL.
Cancer Genet Cytogenet. 2008 Jun;183(2):94-8.
71. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.
Sun J, Chang BL, Isaacs SD, Wiley KE, Wiklund F, Stattin P, Duggan D, Carpten JD, Trock BJ, Partin AW, Walsh PC, Grönberg H, Xu J, Isaacs WB, Zheng SL.
Prostate. 2008 Sep 1;68(12):1257-62.
72. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans.
Sun J, Purcell L, Gao Z, Isaacs SD, Wiley KE, Hsu FC, Liu W, Duggan D, Carpten JD, Grönberg H, Xu J, Chang BL, Partin AW, Walsh PC, Isaacs WB, Zheng SL.
Prostate. 2008 May 15;68(7):691-7.
73. Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation.
Fujita K, Ewing CM, Sokoll LJ, Elliott DJ, Cunningham M, De Marzo AM, Isaacs WB, Pavlovich CP.
Prostate. 2008 Jun 1;68(8):872-82.
74. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.
Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Blondal T, Jakobsdottir M, Stacey SN, Kostic J, Kristinsson KT, Birgisdottir B, Ghosh S, Magnusdottir DN, Thorlacius S, Thorleifsson G, Zheng SL, Sun J, Chang BL, Elmore JB, Breyer JP, McReynolds KM, Bradley KM, Yaspan BL, Wiklund F, Stattin P, Lindström S, Adami HO, McDonnell SK, Schaid DJ, Cunningham JM, Wang L, Cerhan JR, St Sauver JL, Isaacs SD, Wiley KE, Partin AW, Walsh PC, Polo S, Ruiz-Echarri M, Navarrete S, Fuertes F, Saez B, Godino J, Weijerman PC, Swinkels DW, Aben KK, Witjes JA, Suarez BK, Helfand BT, Frigge ML, Kristjansson K, Ober C, Jonsson E, Einarsson GV, Xu J, Gronberg H, Smith JR, Thibodeau SN, Isaacs WB, Catalona WJ, Mayordomo JI, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K.
Nat Genet. 2008 Mar;40(3):281-3. Epub 2008 Feb 10.
75. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients.
Sun J, Lange EM, Isaacs SD, Liu W, Wiley KE, Lange L, Gronberg H, Duggan D, Carpten JD, Walsh PC, Xu J, Chang BL, Isaacs WB, Zheng SL.
Prostate. 2008 Apr 1;68(5):489-97.
76. Cumulative association of five genetic variants with prostate cancer.
Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bälter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H.
N Engl J Med. 2008 Feb 28;358(9):910-9. Epub 2008 Jan 16.
77. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms.
Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM, Isaacs WB.
Prostate. 2008 Feb 15;68(3):306-20.
78. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.
Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley KE, Bälter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W, Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs WB, Grönberg H, Xu J, Carpten JD.
J Natl Cancer Inst. 2007 Dec 19;99(24):1836-44. Epub 2007 Dec 11.
79. The Second Joint Meeting of American Urological Association (AUA)/Japanese Urological Association (JUA) International Program on the 102nd Annual Meeting of American Urological Association at Anaheim 2007.
Ogan K, Kawai K, Gill IS, Naito S, Isaacs WB, Suzuki K, Kibel AS, Kakehi Y, Yoshimura N, Yokoyama O, Chancellor MB, Takahashi S.
Int J Urol. 2007 Dec;14(12):1116-23. No abstract available.
80. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis.
Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, Isaacs WB.
Prostate. 2008 Jan 1;68(1):11-9.
81. Assembly of inflammation-related genes for pathway-focused genetic analysis.
Loza MJ, McCall CE, Li L, Isaacs WB, Xu J, Chang BL.
PLoS One. 2007 Oct 17;2(10):e1035.
82. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.
Zheng SL, Sun J, Cheng Y, Li G, Hsu FC, Zhu Y, Chang BL, Liu W, Kim JW, Turner AR, Gielzak M, Yan G, Isaacs SD, Wiley KE, Sauvageot J, Chen HS, Gurganus R, Mangold LA, Trock BJ, Gronberg H, Duggan D, Carpten JD, Partin AW, Walsh PC, Xu J, Isaacs WB.
J Natl Cancer Inst. 2007 Oct 17;99(20):1525-33. Epub 2007 Oct 9.
83. Viral infections and lower urinary tract symptoms in the third national health and nutrition examination survey.
Sutcliffe S, Rohrmann S, Giovannucci E, Nelson KE, De Marzo AM, Isaacs WB, Nelson WG, Platz EA.
J Urol. 2007 Nov;178(5):2181-5. Epub 2007 Sep 17.
84. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers.
Liu W, Chang BL, Cramer S, Koty PP, Li T, Sun J, Turner AR, Von Kap-Herr C, Bobby P, Rao J, Zheng SL, Isaacs WB, Xu J.
Clin Cancer Res. 2007 Sep 1;13(17):5028-33.
85. Acne and risk of prostate cancer.
Sutcliffe S, Giovannucci E, Isaacs WB, Willett WC, Platz EA.
Int J Cancer. 2007 Dec 15;121(12):2688-92.
86. Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Daugherty SE, Platz EA, Shugart YY, Fallin MD, Isaacs WB, Chatterjee N, Welch R, Huang WY, Hayes RB.
Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42.
87. Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer.
Daugherty SE, Shugart YY, Platz EA, Fallin MD, Isaacs WB, Pfeiffer RM, Welch R, Huang WY, Reding D, Hayes RB.
Prostate. 2007 Oct 1;67(14):1487-97.
88. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers.
Liu W, Ewing CM, Chang BL, Li T, Sun J, Turner AR, Dimitrov L, Zhu Y, Sun J, Kim JW, Zheng SL, Isaacs WB, Xu J.
Genes Chromosomes Cancer. 2007 Nov;46(11):972-80.
89. Genetic etiology of hereditary prostate cancer.
Langeberg WJ, Isaacs WB, Stanford JL.
Front Biosci. 2007 May 1;12:4101-10. Review.
90. Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p.
Chang BL, Liu W, Sun J, Dimitrov L, Li T, Turner AR, Zheng SL, Isaacs WB, Xu J.
Cancer Res. 2007 May 1;67(9):4098-103.
91. Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics.
Camp NJ, Cannon-Albright LA, Farnham JM, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Lange EM, Cooney KA, Tammela TL, Schleutker J, Paiss T, Maier C, Grönberg H, Wiklund F, Emanuelsson M, Isaacs WB; International Consortium for Prostate Cancer Genetics.
Hum Mol Genet. 2007 Jun 1;16(11):1271-8. Epub 2007 May 3.
92. Design, synthesis, and in vitro testing of alpha-methylacyl-CoA racemase inhibitors.
Carnell AJ, Hale I, Denis S, Wanders RJ, Isaacs WB, Wilson BA, Ferdinandusse S.
J Med Chem. 2007 May 31;50(11):2700-7. Epub 2007 May 4.
93. RNASEL Arg462Gln polymorphism and prostate cancer in PLCO.
Daugherty SE, Hayes RB, Yeager M, Andriole GL, Chatterjee N, Huang WY, Isaacs WB, Platz EA.
Prostate. 2007 Jun 1;67(8):849-54.
94. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.
Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K.
Nat Genet. 2007 May;39(5):631-7. Epub 2007 Apr 1.
95. Inflammation in prostate carcinogenesis.
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG.
Nat Rev Cancer. 2007 Apr;7(4):256-69. Review.
96. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies.
Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J.
Prostate. 2007 May 15;67(7):692-700.
97. Germline copy number polymorphisms involving larger than 100 kb are uncommon in normal subjects.
Liu W, Chang B, Li T, Dimitrov L, Kim S, Kim JW, Turner AR, Meyers DA, Trent JM, Zheng SL, Isaacs WB, Xu J.
Prostate. 2007 Feb 15;67(3):227-33.
98. Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis.
Lange EM, Robbins CM, Gillanders EM, Zheng SL, Xu J, Wang Y, White KA, Chang BL, Ho LA, Trent JM, Carpten JD, Isaacs WB, Cooney KA.
Hum Genet. 2007 Mar;121(1):49-55. Epub 2006 Nov 21.
99. Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk.
Wang X, Wang F, Taniguchi K, Seelan RS, Wang L, Zarfas KE, McDonnell SK, Qian C, Pan K, Lu Y, Shridhar V, Couch FJ, Tindall DJ, Beebe-Dimmer JL, Cooney KA, Isaacs WB, Jacobsen SJ, Schaid DJ, Thibodeau SN, Liu W.
Cancer Res. 2006 Nov 1;66(21):10302-7.
100. A novel role of myosin VI in human prostate cancer.
Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J.
Am J Pathol. 2006 Nov;169(5):1843-54.
101. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.
Lindström S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, Bälter KA, Brookes AJ, Sun J, Chang BL, Liu W, Li G, Isaacs WB, Adolfsson J, Grönberg H, Xu J.
Prostate. 2006 Dec 1;66(16):1729-43.
102. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics.
Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S, Thibodeau SN, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Badzioch M, Bishop DT, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Guy M, Hsieh CL, Halpern J, Balise RR, Oakley-Girvan I, Whittemore AS, Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Friedrichsen DM, Deutsch K, Kolb S, Janer M, Hood L, Ostrander EA, Stanford JL, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Lange EM, Ho LA, Beebe-Dimmer JL, Wood DP, Cooney KA, Seminara D, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TL, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Grönberg H, Camp NJ, Farnham J, Cannon-Albright LA, Catalona WJ, Suarez BK, Roehl KA.
Hum Genet. 2006 Nov;120(4):471-85. Epub 2006 Aug 25.
103. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study.
Zheng SL, Liu W, Wiklund F, Dimitrov L, Bälter K, Sun J, Adami HO, Johansson JE, Sun J, Chang B, Loza M, Turner AR, Bleecker ER, Meyers DA, Carpten JD, Duggan D, Isaacs WB, Xu J, Grönberg H.
Prostate. 2006 Oct 1;66(14):1556-64.
104. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array.
Liu W, Chang B, Sauvageot J, Dimitrov L, Gielzak M, Li T, Yan G, Sun J, Sun J, Adams TS, Turner AR, Kim JW, Meyers DA, Zheng SL, Isaacs WB, Xu J.
Genes Chromosomes Cancer. 2006 Nov;45(11):1018-32.
105. Is there a role for a low-carbohydrate ketogenic diet in the management of prostate cancer?
Mavropoulos JC, Isaacs WB, Pizzo SV, Freedland SJ.
Urology. 2006 Jul;68(1):15-8. Review. No abstract available.
106. Germline ATBF1 mutations and prostate cancer risk.
Xu J, Sauvageot J, Ewing CM, Sun J, Liu W, Isaacs SD, Wiley KE, Diaz L, Zheng SL, Walsh PC, Isaacs WB.
Prostate. 2006 Jul 1;66(10):1082-5.
107. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration.
Sutcliffe S, Zenilman JM, Ghanem KG, Jadack RA, Sokoll LJ, Elliott DJ, Nelson WG, De Marzo AM, Cole SR, Isaacs WB, Platz EA.
J Urol. 2006 May;175(5):1937-42.
108. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk.
Sun J, Wiklund F, Hsu FC, Bälter K, Zheng SL, Johansson JE, Chang B, Liu W, Li T, Turner AR, Li L, Li G, Adami HO, Isaacs WB, Xu J, Grönberg H.
Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):480-5.
109. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk.
Sun J, Hsu FC, Turner AR, Zheng SL, Chang BL, Liu W, Isaacs WB, Xu J.
Prostate. 2006 May 15;66(7):728-37.
110. Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines.
Gu Y, Li H, Miki J, Kim KH, Furusato B, Sesterhenn IA, Chu WS, McLeod DG, Srivastava S, Ewing CM, Isaacs WB, Rhim JS.
Exp Cell Res. 2006 Apr 1;312(6):831-43. Epub 2006 Jan 17.
111. Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function.
Zheng SL, Ju JH, Chang BL, Ortner E, Sun J, Isaacs SD, Sun J, Wiley KE, Liu W, Zemedkun M, Walsh PC, Ferretti J, Gruschus J, Isaacs WB, Gelmann EP, Xu J.
Cancer Res. 2006 Jan 1;66(1):69-77.
112. Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effect.
Chang BL, Lange EM, Dimitrov L, Valis CJ, Gillanders EM, Lange LA, Wiley KE, Isaacs SD, Wiklund F, Baffoe-Bonnie A, Langefeld CD, Zheng SL, Matikainen MP, Ikonen T, Fredriksson H, Tammela T, Walsh PC, Bailey-Wilson JE, Schleutker J, Gronberg H, Cooney KA, Isaacs WB, Suh E, Trent JM, Xu J.
Hum Genet. 2006 Feb;118(6):716-24. Epub 2005 Nov 23.
113. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk.
Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC, Dimitrov L, Chang B, Turner AR, Liu W, Adami HO, Suh E, Moore JH, Zheng SL, Isaacs WB, Trent JM, Grönberg H.
Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2563-8.
114. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study.
Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC Jr, Kane CJ.
J Clin Oncol. 2005 Oct 20;23(30):7546-54.
115. Obesity and capsular incision at the time of open retropubic radical prostatectomy.
Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, Epstein JI, Partin AW.
J Urol. 2005 Nov;174(5):1798-801; discussion 1801.
116. Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP.
Lindström S, Wiklund F, Jonsson BA, Adami HO, Bälter K, Brookes AJ, Xu J, Zheng SL, Isaacs WB, Adolfsson J, Grönberg H.
Hum Genet. 2005 Dec;118(3-4):339-47. Epub 2005 Sep 28.
117. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, Isaacs WB, Partin AW.
J Urol. 2005 Sep;174(3):919-22.
118. Molecular prostate cancer pathology: current issues and achievements.
Schalken JA, Bergh A, Bono A, Foster C, Gospadarowicz M, Isaacs WB, Rubin M, Schröder F, Tribukait B, Tsukamotot T, Wiklund P.
Scand J Urol Nephrol Suppl. 2005 May;(216):82-93. Review.
119. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics.
Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TLj, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D; ACTANE Consortium.
Am J Hum Genet. 2005 Aug;77(2):219-29. Epub 2005 Jun 29.
120. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region.
Baffoe-Bonnie AB, Smith JR, Stephan DA, Schleutker J, Carpten JD, Kainu T, Gillanders EM, Matikainen M, Teslovich TM, Tammela T, Sood R, Balshem AM, Scarborough SD, Xu J, Isaacs WB, Trent JM, Kallioniemi OP, Bailey-Wilson JE.
Hum Genet. 2005 Aug;117(4):307-16. Epub 2005 May 20. Erratum in: Hum Genet. 2005 Nov;118(2):307.
121. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years.
Freedland SJ, Isaacs WB, Mangold LA, Yiu SK, Grubb KA, Partin AW, Epstein JI, Walsh PC, Platz EA.
Clin Cancer Res. 2005 Apr 15;11(8):2883-8.
122. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grönberg H.
J Natl Cancer Inst. 2005 Apr 6;97(7):525-32.
123. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
Zha S, Isaacs WB.
Mol Cancer Res. 2005 Feb;3(2):110-8.
124. Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease.
Chang BL, Isaacs SD, Wiley KE, Gillanders EM, Zheng SL, Meyers DA, Walsh PC, Trent JM, Xu J, Isaacs WB.
Prostate. 2005 Sep 1;64(4):356-61.
125. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk.
Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, Zheng SL, Chang BL, Friedrichsen DM, Stanford JL, Ostrander EA, Chinnaiyan AM, Rubin MA, Xu J, Thibodeau SN, Friedman SL, Martignetti JA.
Cancer Res. 2005 Feb 15;65(4):1213-22.
126. Evidence for a general cancer susceptibility locus at 3p24 in families with hereditary prostate cancer.
Chang BL, Gillanders EM, Isaacs SD, Wiley KE, Adams T, Turner AR, Zheng SL, Meyers DA, Carpten JD, Walsh PC, Trent JM, Xu J, Isaacs WB.
Cancer Lett. 2005 Mar 10;219(2):177-82.
127. Modulation of CXCL14 (BRAK) expression in prostate cancer.
Schwarze SR, Luo J, Isaacs WB, Jarrard DF.
Prostate. 2005 Jun 15;64(1):67-74.
128. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.
Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB.
Prostate. 2005 Jun 1;63(4):316-23.
129. Sequence variants in the 3'-->5' deoxyribonuclease TREX2: identification in a genetic screen and effects on catalysis by the recombinant proteins.
Perrino FW, Krol A, Harvey S, Zheng SL, Horita DA, Hollis T, Meyers DA, Isaacs WB, Xu J.
Adv Enzyme Regul. 2004;44:37-49. No abstract available.
130. The role of inflammation in the pathogenesis of prostate cancer.
Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB.
J Urol. 2004 Nov;172(5 Pt 2):S6-11; discussion S11-2. Review.
131. Prostate carcinogenesis and inflammation: emerging insights.
Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG.
Carcinogenesis. 2005 Jul;26(7):1170-81. Epub 2004 Oct 21. Review.
132. Interleukin-6 sequence variants are not associated with prostate cancer risk.
Sun J, Hedelin M, Zheng SL, Adami HO, Bensen J, Augustsson-Bälter K, Chang B, Adolfsson J, Adams T, Turner A, Meyers DA, Isaacs WB, Xu J, Grönberg H.
Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1677-9. No abstract available.
133. Explaining racial differences in prostate cancer in the United States: sociology or biology?
Freedland SJ, Isaacs WB.
Prostate. 2005 Feb 15;62(3):243-52. Review.
134. Cyclooxygenases in cancer: progress and perspective.
Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM.
Cancer Lett. 2004 Nov 8;215(1):1-20. Review.
135. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, De Marzo AM, Nelson WG, Pavlovich CP.
J Urol. 2004 Oct;172(4 Pt 1):1501-3.
136. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays.
Faith DA, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, Mangold LA, Walsh PC, Partin AW, Platz EA, Luo J, De Marzo AM.
Prostate. 2004 Nov 1;61(3):215-27.
137. Combined genome-wide scan for prostate cancer susceptibility genes.
Gillanders EM, Xu J, Chang BL, Lange EM, Wiklund F, Bailey-Wilson JE, Baffoe-Bonnie A, Jones M, Gildea D, Riedesel E, Albertus J, Isaacs SD, Wiley KE, Mohai CE, Matikainen MP, Tammela TL, Zheng SL, Brown WM, Rökman A, Carpten JD, Meyers DA, Walsh PC, Schleutker J, Gronberg H, Cooney KA, Isaacs WB, Trent JM.
J Natl Cancer Inst. 2004 Aug 18;96(16):1240-7.
138. Mutational analysis of PINX1 in hereditary prostate cancer.
Hawkins GA, Chang BL, Zheng SL, Isaacs SD, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Xu J, Isaacs WB.
Prostate. 2004 Sep 1;60(4):298-302.
139. Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage.
Xu J, Langefeld CD, Zheng SL, Gillanders EM, Chang BL, Isaacs SD, Williams AH, Wiley KE, Dimitrov L, Meyers DA, Walsh PC, Trent JM, Isaacs WB.
Hum Genet. 2004 Aug;115(3):255-62. Epub 2004 Jun 5.
140. Improved biomarkers for prostate cancer: a definite need.
Carter HB, Isaacs WB.
J Natl Cancer Inst. 2004 Jun 2;96(11):813-5. No abstract available.
141. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study.
Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, Adams TS, Meyers DA, Isaacs WB, Xu J, Grönberg H.
Cancer Res. 2004 Apr 15;64(8):2918-22.
142. Identification of aryl hydrocarbon receptor as a putative Wnt/beta-catenin pathway target gene in prostate cancer cells.
Chesire DR, Dunn TA, Ewing CM, Luo J, Isaacs WB.
Cancer Res. 2004 Apr 1;64(7):2523-33.
143. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer.
Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, Walsh PC, Meyers DA, Isaacs WB, Xu J.
Cancer Res. 2004 Mar 15;64(6):1997-9.
144. Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG.
Cancer Res. 2004 Mar 15;64(6):1975-86.
145. Expression mapping at 12p12-13 in advanced prostate carcinoma.
Kibel AS, Huagen J, Guo C, Isaacs WB, Yan Y, Pienta KJ, Goodfellow PJ.
Int J Cancer. 2004 May 1;109(5):668-72.
146. Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families.
Friedrichsen DM, Stanford JL, Isaacs SD, Janer M, Chang BL, Deutsch K, Gillanders E, Kolb S, Wiley KE, Badzioch MD, Zheng SL, Walsh PC, Jarvik GP, Hood L, Trent JM, Isaacs WB, Ostrander EA, Xu J.
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1939-44. Epub 2004 Feb 9.
147. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment.
De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG.
J Cell Biochem. 2004 Feb 15;91(3):459-77. Review.
148. Looking beyond morphology: cancer gene expression profiling using DNA microarrays.
Luo J, Isaacs WB, Trent JM, Duggan DJ.
Cancer Invest. 2003;21(6):937-49. Review.
149. Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci.
Brown WM, Lange EM, Chen H, Zheng SL, Chang B, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Xu J, Cooney KA.
Br J Cancer. 2004 Jan 26;90(2):510-4.
150. Beta-catenin signaling in prostate cancer: an early perspective.
Chesire DR, Isaacs WB.
Endocr Relat Cancer. 2003 Dec;10(4):537-60. Review.
151. Androgen receptor outwits prostate cancer drugs.
Isaacs JT, Isaacs WB.
Nat Med. 2004 Jan;10(1):26-7. No abstract available.
152. Cadherin-6: a new prognostic marker for renal cell carcinoma.
Paul R, Necknig U, Busch R, Ewing CM, Hartung R, Isaacs WB.
J Urol. 2004 Jan;171(1):97-101.
153. Molecular pathways to prostate cancer.
Gonzalgo ML, Isaacs WB.
J Urol. 2003 Dec;170(6 Pt 1):2444-52. Review.
154. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB.
Cancer Res. 2003 Nov 1;63(21):7365-76.
155. Human prostate cancer precursors and pathobiology.
De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG.
Urology. 2003 Nov;62(5 Suppl 1):55-62. Review.
156. Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families.
Xu J, Gillanders EM, Isaacs SD, Chang BL, Wiley KE, Zheng SL, Jones M, Gildea D, Riedesel E, Albertus J, Freas-Lutz D, Markey C, Meyers DA, Walsh PC, Trent JM, Isaacs WB.
Prostate. 2003 Dec 1;57(4):320-5.
157. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates.
Xiang Y, Wang Z, Murakami J, Plummer S, Klein EA, Carpten JD, Trent JM, Isaacs WB, Casey G, Silverman RH.
Cancer Res. 2003 Oct 15;63(20):6795-801.
158. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer.
Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J.
Br J Cancer. 2003 Oct 20;89(8):1524-9.
159. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.
Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB.
Prostate. 2003 Oct 1;57(2):134-9.
160. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy.
Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI.
Am J Surg Pathol. 2003 Aug;27(8):1128-33.
161. Prostate cancer.
Nelson WG, De Marzo AM, Isaacs WB.
N Engl J Med. 2003 Jul 24;349(4):366-81. Review. No abstract available.
162. Evaluation of DLC1 as a prostate cancer susceptibility gene: mutation screen and association study.
Zheng SL, Mychaleckyj JC, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Chang BL, von Kap-Herr C, Carpten JD, Pettenati M, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu J.
Mutat Res. 2003 Jul 25;528(1-2):45-53.
163. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk.
Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J.
Int J Cancer. 2003 Sep 1;106(3):375-8.
164. Xq27-28 deletions in prostate carcinoma.
Kibel AS, Faith DA, Bova GS, Isaacs WB.
Genes Chromosomes Cancer. 2003 Aug;37(4):381-8.
165. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
Chang BL, Zheng SL, Isaacs SD, Turner AR, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J.
Prostate. 2003 Jun 15;56(1):37-44.
166. Familial aggregation of bothersome benign prostatic hyperplasia symptoms.
Pearson JD, Lei HH, Beaty TH, Wiley KE, Isaacs SD, Isaacs WB, Stoner E, Walsh PC.
Urology. 2003 Apr;61(4):781-5.
167. Pathological and molecular aspects of prostate cancer.
DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI.
Lancet. 2003 Mar 15;361(9361):955-64. Review.
168. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.
Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Chang B, Turner AR, Ewing CM, Wiley KE, Hawkins GA, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB.
Am J Hum Genet. 2003 Jan;72(1):208-12. Epub 2002 Dec 6.
169. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor.
Chesire DR, Isaacs WB.
Oncogene. 2002 Dec 5;21(55):8453-69.
170. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk.
Zheng SL, Chang BL, Faith DA, Johnson JR, Isaacs SD, Hawkins GA, Turner A, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J.
Cancer Res. 2002 Nov 15;62(22):6485-8.
171. Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk.
Hawkins GA, Cramer SD, Zheng SL, Isaacs SD, Wiley KE, Chang BL, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J.
Prostate. 2002 Nov 1;53(3):175-8.
172. Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk.
Hawkins GA, Mychaleckyj JC, Zheng SL, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang BL, Ewing CM, Bujnovszky P, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J.
Cancer Genet Cytogenet. 2002 Aug;137(1):1-7.
173. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.
Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA.
Nat Genet. 2002 Oct;32(2):321-5. Epub 2002 Sep 16.
174. Mutational analysis of ETV6 in prostate carcinoma.
Kibel AS, Faith DA, Bova GS, Isaacs WB.
Prostate. 2002 Sep 1;52(4):305-10.
175. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.
Chesire DR, Ewing CM, Gage WR, Isaacs WB.
Oncogene. 2002 Apr 18;21(17):2679-94.
176. Associations between hOGG1 sequence variants and prostate cancer susceptibility.
Xu J, Zheng SL, Turner A, Isaacs SD, Wiley KE, Hawkins GA, Chang BL, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB.
Cancer Res. 2002 Apr 15;62(8):2253-7.
177. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM.
Cancer Res. 2002 Apr 15;62(8):2220-6.
178. Transmission/disequilibrium tests of androgen receptor and glutathione S-transferase pi variants in prostate cancer families.
Ho GY, Knapp M, Freije D, Nelson WG, Smith JR, Carpten JD, Bailey-Wilson JE, Beaty TH, Petersen G, Xu J, Kamensky V, Walsh PC, Isaacs WB.
Int J Cancer. 2002 Apr 20;98(6):938-42.
179. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk.
Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu J.
Hum Genet. 2002 Feb;110(2):122-9. Epub 2002 Jan 23.
180. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility.
Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu J.
Cancer Res. 2002 Mar 15;62(6):1784-9.
181. High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells.
Takaha N, Hawkins AL, Griffin CA, Isaacs WB, Coffey DS.
Cancer Res. 2002 Feb 1;62(3):647-51.
182. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB.
Cancer Res. 2001 Dec 15;61(24):8617-23.
183. Multiple antibodies to titin immunoreact with AHNAK and localize to the mitotic spindle machinery.
Wernyj RP, Ewing CM, Isaacs WB.
Cell Motil Cytoskeleton. 2001 Oct;50(2):101-13.
184. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells.
Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, Bova GS, Isaacs WB, Brooks JD, DeWeese TL, De Marzo AM, Nelson WG.
Am J Pathol. 2001 Nov;159(5):1815-26.
185. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer.
Chang B, Zheng SL, Isaacs SD, Wiley KE, Carpten JD, Hawkins GA, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu J.
Int J Cancer. 2001 Nov 20;95(6):354-9.
186. A glimpse into the future.
Hsing AW, Chang L, Nomura AM, Isaacs WB, Armenian HK.
Epidemiol Rev. 2001;23(1):2. No abstract available.
187. Methylation and mutational analysis of p27(kip1) in prostate carcinoma.
Kibel AS, Christopher M, Faith DA, Bova GS, Goodfellow PJ, Isaacs WB.
Prostate. 2001 Sep 15;48(4):248-53.
188. A novel human cell culture model for the study of familial prostate cancer.
Yasunaga Y, Nakamura K, Ewing CM, Isaacs WB, Hukku B, Rhim JS.
Cancer Res. 2001 Aug 15;61(16):5969-73.
189. Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23.
Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang B, Ewing CM, Bujnovszky P, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB.
Am J Hum Genet. 2001 Aug;69(2):341-50. Epub 2001 Jul 6.
190. Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families.
Zheng SL, Xu J, Isaacs SD, Wiley K, Chang B, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB.
Hum Genet. 2001 May;108(5):430-5.
191. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.
Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB.
Cancer Res. 2001 Jun 15;61(12):4683-8.
192. Linkage of prostate cancer susceptibility loci to chromosome 1.
Xu J, Zheng SL, Chang B, Smith JR, Carpten JD, Stine OC, Isaacs SD, Wiley KE, Henning L, Ewing C, Bujnovszky P, Bleeker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB.
Hum Genet. 2001 Apr;108(4):335-45.
193. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer.
Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, Bujnovszky P, Chang B, Bailey-Wilson J, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB.
Am J Hum Genet. 2001 Apr;68(4):901-11. Epub 2001 Mar 14.
194. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1.
Nelson CP, Kidd LC, Sauvageot J, Isaacs WB, De Marzo AM, Groopman JD, Nelson WG, Kensler TW.
Cancer Res. 2001 Jan 1;61(1):103-9.
195. Detection and analysis of beta-catenin mutations in prostate cancer.
Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB.
Prostate. 2000 Dec 1;45(4):323-34.
196. No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study.
Shepard TF, Platz EA, Kantoff PW, Nelson WG, Isaacs WB, Freije D, Febbo PG, Stampfer MJ, Giovannucci E.
Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1267-8. No abstract available.
197. Absence of HinfI Restriction Abnormalities in Renal Oncocytoma Mitochondrial DNA.
Brooks JD, Marshall FF, Isaacs WB, Johns DR.
Mol Urol. 1999;3(1):1-3.
198. Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma.
Kibel AS, Faith DA, Bova GS, Isaacs WB.
J Urol. 2000 Jul;164(1):192-6.
199. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas.
Tchou JC, Lin X, Freije D, Isaacs WB, Brooks JD, Rashid A, De Marzo AM, Kanai Y, Hirohashi S, Nelson WG.
Int J Oncol. 2000 Apr;16(4):663-76.
200. G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma.
Kibel AS, Isaacs WB.
Urology. 2000 Mar;55(3):316-22. No abstract available.
201. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB.
Cancer Res. 1999 Dec 1;59(23):5975-9.
202. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.
Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW.
Cancer Res. 1999 Nov 15;59(22):5830-5.
203. Deletion mapping at 12p12-13 in metastatic prostate cancer.
Kibel AS, Freije D, Isaacs WB, Bova GS.
Genes Chromosomes Cancer. 1999 Jul;25(3):270-6.
204. Methylation of the CD44 metastasis suppressor gene in human prostate cancer.
Lou W, Krill D, Dhir R, Becich MJ, Dong JT, Frierson HF Jr, Isaacs WB, Isaacs JT, Gao AC.
Cancer Res. 1999 May 15;59(10):2329-31.
205. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer.
Wilkens EP, Freije D, Xu J, Nusskern DR, Suzuki H, Isaacs SD, Wiley K, Bujnovsky P, Meyers DA, Walsh PC, Isaacs WB.
Prostate. 1999 Jun 1;39(4):280-4.
206. Identification of 12p as a region of frequent deletion in advanced prostate cancer.
Kibel AS, Schutte M, Kern SE, Isaacs WB, Bova GS.
Cancer Res. 1998 Dec 15;58(24):5652-5.
207. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.
Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N.
Cancer Res. 1998 Dec 1;58(23):5310-4.
208. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer.
Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL.
Cancer Res. 1998 Dec 1;58(23):5280-4.
209. Molecular genetics of prostate cancer: clinical applications.
Morton RA Jr, Isaacs WB.
J Natl Med Assoc. 1998 Nov;90(11 Suppl):S728-31. Review. No abstract available.
210. P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer.
Jarrard DF, Paul R, van Bokhoven A, Nguyen SH, Bova GS, Wheelock MJ, Johnson KR, Schalken J, Bussemakers M, Isaacs WB.
Clin Cancer Res. 1997 Nov;3(11):2121-8.
211. Vitamin D receptor polymorphisms and lethal prostate cancer.
Kibel AS, Isaacs SD, Isaacs WB, Bova GS.
J Urol. 1998 Oct;160(4):1405-9.
212. Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy.
Bova GS, Partin AW, Isaacs SD, Carter BS, Beaty TL, Isaacs WB, Walsh PC.
J Urol. 1998 Sep;160(3 Pt 1):660-3.
213. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia.
Brooks JD, Weinstein M, Lin X, Sun Y, Pin SS, Bova GS, Epstein JI, Isaacs WB, Nelson WG.
Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):531-6.
214. E1A transformed normal human prostate epithelial cells contain a 16q deletion.
Chin RK, Hawkins AL, Isaacs WB, Griffin CA.
Cancer Genet Cytogenet. 1998 Jun;103(2):155-63.
215. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.
Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL.
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50.
216. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS.
Cancer Res. 1998 Jan 15;58(2):204-9.
217. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D.
Cancer Res. 1997 Nov 15;57(22):4997-5000.
218. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1.
Grönberg H, Xu J, Smith JR, Carpten JD, Isaacs SD, Freije D, Bova GS, Danber JE, Bergh A, Walsh PC, Collins FS, Trent JM, Meyers DA, Isaacs WB.
Cancer Res. 1997 Nov 1;57(21):4707-9. Erratum in: Cancer Res 1998 Jul 15;58(14):3191.
219. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus.
Grönberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, Meyers DA, Collins FS, Trent JM, Walsh PC, Isaacs WB.
JAMA. 1997 Oct 15;278(15):1251-5.
220. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer.
Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, Schalken JA.
Int J Cancer. 1997 Aug 22;74(4):374-7.
221. Cadherin-6, a cell adhesion molecule specifically expressed in the proximal renal tubule and renal cell carcinoma.
Paul R, Ewing CM, Robinson JC, Marshall FF, Johnson KR, Wheelock MJ, Isaacs WB.
Cancer Res. 1997 Jul 1;57(13):2741-8.
222. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker.
Lee WH, Isaacs WB, Bova GS, Nelson WG.
Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):443-50.
223. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG, Isaacs WB.
Genes Chromosomes Cancer. 1997 Jun;19(2):90-6.
224. Genomic organization of the human KAI1 metastasis-suppressor gene.
Dong JT, Isaacs WB, Barrett JC, Isaacs JT.
Genomics. 1997 Apr 1;41(1):25-32.
225. The cadherin cell-cell adhesion pathway in prostate cancer progression.
Paul R, Ewing CM, Jarrard DF, Isaacs WB.
Br J Urol. 1997 Mar;79 Suppl 1:37-43. Review.
226. Tumour-suppressor genes in prostatic oncogenesis: a positional approach.
Bookstein R, Bova GS, MacGrogan D, Levy A, Isaacs WB.
Br J Urol. 1997 Mar;79 Suppl 1:28-36. Review.
227. Molecular advances in prostate cancer.
Dong JT, Isaacs WB, Isaacs JT.
Curr Opin Oncol. 1997 Jan;9(1):101-7. Review.
228. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search.
Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB.
Science. 1996 Nov 22;274(5291):1371-4.
229. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss.
Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT.
Cancer Res. 1996 Oct 1;56(19):4387-90.
230. An uncertain role for p53 gene alterations in human prostate cancers.
Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB.
Cancer Res. 1996 Aug 15;56(16):3814-22.
231. Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue.
Morton RA Jr, Watkins JJ, Bova GS, Wales MM, Baylin SB, Isaacs WB.
J Urol. 1996 Aug;156(2 Pt 1):512-6.
232. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH.
Cancer Res. 1996 Jul 1;56(13):3091-102.
233. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22.
MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R.
Genomics. 1996 Jul 1;35(1):55-65.
234. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer.
Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB.
Genomics. 1996 Jul 1;35(1):46-54.
235. DPC4 gene in various tumor types.
Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, Meltzer PS, Hahn SA, Kern SE.
Cancer Res. 1996 Jun 1;56(11):2527-30.
236. Review of allelic loss and gain in prostate cancer.
Bova GS, Isaacs WB.
World J Urol. 1996;14(5):338-46. Review.
237. DNA methylation, molecular genetic, and linkage studies in prostate cancer.
Jarrard DF, Bova GS, Isaacs WB.
Prostate Suppl. 1996;6:36-44. Review.
238. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues.
Jarrard DF, Bussemakers MJ, Bova GS, Isaacs WB.
Clin Cancer Res. 1995 Dec;1(12):1471-8.
239. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.
Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB.
Cancer Res. 1995 Nov 15;55(22):5195-9.
240. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function.
Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC, Isaacs WB.
Cancer Res. 1995 Nov 1;55(21):4813-7.
241. Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders.
Bell FW, Klausner JS, Hayden DW, Lund EM, Liebenstein BB, Feeney DA, Johnston SD, Shivers JL, Ewing CM, Isaacs WB.
J Vet Intern Med. 1995 May-Jun;9(3):149-53.
242. The E-cadherin cell-cell adhesion pathway in urologic malignancies.
Morton RA Jr, Ewing CM, Watkins JJ, Isaacs WB.
World J Urol. 1995;13(6):364-8. Review.
243. Molecular genetics of prostate cancer.
Isaacs WB.
Cancer Surv. 1995;25:357-79. Review.
244. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas.
Brooks JD, Bova GS, Isaacs WB.
Prostate. 1995 Jan;26(1):35-9.
245. Molecular biology of prostate cancer progression.
Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM.
Cancer Surv. 1995;23:19-32. Review.
246. Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney.
Schoenberg M, Cairns P, Brooks JD, Marshall FF, Epstein JI, Isaacs WB, Sidransky D.
Genes Chromosomes Cancer. 1995 Jan;12(1):76-80.
247. TaqI polymorphism of the human MXI1 gene.
Bova GS, Wechsler DS, Van Dang C, Isaacs WB.
Hum Mol Genet. 1994 Dec;3(12):2266. No abstract available.
248. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.
Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG.
Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11733-7.
249. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells.
Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT.
Prostate. 1994 Nov;25(5):249-65. Review.
250. Molecular biology of prostate cancer.
Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM.
Semin Oncol. 1994 Oct;21(5):514-21. Review.
251. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.
Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA.
Cancer Res. 1994 Jul 15;54(14):3929-33.
252. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo.
Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB.
Prostate. 1994 May;24(5):244-51.
253. Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer.
Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER.
Biochem Biophys Res Commun. 1994 Jan 14;198(1):74-80.
254. Assignment of the human alpha-catenin gene (CTNNA1) to chromosome 5q21-q22.
McPherson JD, Morton RA, Ewing CM, Wasmuth JJ, Overhauser J, Nagafuchi A, Tsukita S, Isaacs WB.
Genomics. 1994 Jan 1;19(1):188-90. No abstract available.
255. Genetic alterations in prostate cancer.
Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM.
Cold Spring Harb Symp Quant Biol. 1994;59:653-9. Review.
256. Tumor suppressor gene allelic loss in human renal cancers.
Brooks JD, Bova GS, Marshall FF, Isaacs WB.
J Urol. 1993 Oct;150(4):1278-83.
257. Hereditary prostate cancer: epidemiologic and clinical features.
Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC.
J Urol. 1993 Sep;150(3):797-802. Review. No abstract available.
258. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells.
Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB.
Cancer Res. 1993 Aug 1;53(15):3585-90.
259. Molecular and cellular markers for metastatic prostate cancer.
Rinker-Schaeffer CW, Isaacs WB, Isaacs JT.
Cancer Metastasis Rev. 1993 Mar;12(1):3-10. Review. No abstract available.
260. Cerebral injury: are manipulations of carbon dioxide beneficial?
Jacobsen WK, Isaacs WB.
J Neurosurg Anesthesiol. 1993 Jan;5(1):59-61. Review. No abstract available.
261. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.
Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debruyne FM, Isaacs WB.
Cancer Res. 1992 Sep 15;52(18):5104-9.
262. Association of titin and myosin heavy chain in developing skeletal muscle.
Isaacs WB, Kim IS, Struve A, Fulton AB.
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7496-500.
263. Androgen receptor gene mutations in human prostate cancer.
Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER.
Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6319-23.
264. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11.
Ichikawa T, Ichikawa Y, Dong J, Hawkins AL, Griffin CA, Isaacs WB, Oshimura M, Barrett JC, Isaacs JT.
Cancer Res. 1992 Jun 15;52(12):3486-90.
265. Molecular biology of bladder cancer.
Borland RN, Brendler CB, Isaacs WB.
Hematol Oncol Clin North Am. 1992 Feb;6(1):31-9. Review.
266. Comparative aspects of multistep prostatic carcinogenesis in humans and rodents.
Isaacs JT, Isaacs WB, Schalken J.
Prog Clin Biol Res. 1992;376:261-88. Review. No abstract available.
267. Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility.
Pienta KJ, Murphy BC, Isaacs WB, Isaacs JT, Coffey DS.
Prostate. 1992;20(3):233-41.
268. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.
Isaacs WB, Carter BS, Ewing CM.
Cancer Res. 1991 Sep 1;51(17):4716-20.
269. Titin, a huge, elastic sarcomeric protein with a probable role in morphogenesis.
Fulton AB, Isaacs WB.
Bioessays. 1991 Apr;13(4):157-61. Review.
270. The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells.
Pienta KJ, Isaacs WB, Vindivich D, Coffey DS.
J Urol. 1991 Jan;145(1):199-202.
271. Genetic changes associated with prostate cancer in humans.
Isaacs WB, Carter BS.
Cancer Surv. 1991;11:15-24. Review.
272. ras gene mutations in human prostate cancer.
Carter BS, Epstein JI, Isaacs WB.
Cancer Res. 1990 Nov 1;50(21):6830-2.
273. Allelic loss of chromosomes 16q and 10q in human prostate cancer.
Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB.
Proc Natl Acad Sci U S A. 1990 Nov;87(22):8751-5.
274. Differential effects of growth factor antagonists on neoplastic and normal prostatic cells.
Morton RA, Isaacs JT, Isaacs WB.
Prostate. 1990;17(4):327-36.
275. New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy.
Isaacs WB, Isaacs JT, Kyprianou N, Burgers JK, Alexander RB, Partin AW, Mohler JL, Marshall FF, Coffey DS.
Eur Urol. 1990;18 Suppl 2:33-5. Review. No abstract available.
276. Biosynthesis of titin in cultured skeletal muscle cells.
Isaacs WB, Kim IS, Struve A, Fulton AB.
J Cell Biol. 1989 Nov;109(5):2189-95.
277. Assembly of vimentin in cultured cells varies with cell type.
Isaacs WB, Cook RK, Van Atta JC, Redmond CM, Fulton AB.
J Biol Chem. 1989 Oct 25;264(30):17953-60.
278. Cotranslational assembly of myosin heavy chain in developing cultured skeletal muscle.
Isaacs WB, Fulton AB.
Proc Natl Acad Sci U S A. 1987 Sep;84(17):6174-8.
279. Time lapse videomicroscopic identification of Dunning R-3327 adenocarcinoma and normal rat prostate cells.
Mohler JL, Partin AW, Isaacs WB, Coffey DS.
J Urol. 1987 Mar;137(3):544-7.
280. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers.
Isaacs JT, Isaacs WB, Feitz WF, Scheres J.
Prostate. 1986;9(3):261-81.
281. Immunological localization and quantitation of the androgen-dependent secretory protease of the canine prostate.
Isaacs WB, Shaper JH.
Endocrinology. 1985 Oct;117(4):1512-20.
282. Immunogold probes for electron microscopy: evaluation of staining by fluorescence microscopy.
Alexander RB, Isaacs WB, Barrack ER.
J Histochem Cytochem. 1985 Oct;33(10):995-1000.
283. The predominant protein of canine seminal plasma is an enzyme.
Isaacs WB, Coffey DS.
J Biol Chem. 1984 Sep 25;259(18):11520-6.
284. Structural and functional components in normal and hyperplastic canine prostates.
Isaacs WB.
Prog Clin Biol Res. 1984;145:307-31. No abstract available.
285. Isolation and characterization of the major androgen-dependent glycoprotein of canine prostatic fluid.
Isaacs WB, Shaper JH.
J Biol Chem. 1983 May 25;258(10):6610-5.
286. The relationship of cellular structure and function: the matrix system.
Isaacs JT, Barrack ER, Isaacs WB, Coffey DS.
Prog Clin Biol Res. 1981;75A:1-24. No abstract available.
287. Differential effects of estrogen treatment on canine seminal plasma components.
Isaacs JT, Isaacs WB, Wheaton LG, Coffey DS.
Invest Urol. 1980 May;17(6):495-8.
288. Models for development of nonreceptor methods for distinguishing androgen-sensitive and -insensitive prostatic tumors.
Isaacs JT, Isaacs WB, Coffey DS.
Cancer Res. 1979 Jul;39(7 Pt 1):2652-9.
    BOOK CHAPTERS
  1. Isaacs, J.T., Barrack, E.R., Isaacs, W.B. and Coffey, D.S. The Relationship of Cellular Structure and Function: The Matrix System. In: The Prostatic Cell: Structure and Function (Murphy, G.P., Sandberg, A.A. and Karr, J.P., Eds.), Part A, Alan R. Liss, New York, pp. 1-24, 1981.

  2. Isaacs, W.B. Structural and Functional Components in Normal and Hyperplastic Canine Prostates. In New Approaches to the Study of Benign Prostatic Hyperplasia (Kimball, E., Buhl, A. and Carter, D., Eds.), Alan R. Liss, New York, pp. 307-311, 1984.

  3. Isaacs, W.B. and Fulton, A.B. Assembly of Cytoskeletal Proteins in Cultured Chicken Cells. In: Cellular and Molecular Biology of Muscle Development (Fischman, D. and Keddes, L., Eds.), Alan R. Liss, New York, pp. 137-146, 1989.

  4. Isaacs, W.B. , Morton, R.A., Carter, B.S., Ewing, C.M., Chevrier, M., and Epstein, J.I. Genomic Alterations in Prostatic Cancer. In: Molecular and Cellular Biology of Prostate Cancer. (Karr, J.P., Coffey, D.S., Smith, R.G. and Tindall, D.J., Eds.), Plenum Press, New York, pp. 289-297, 1991.

  5. Isaacs, W.B. and Carter, B.S. Genetic Changes Associated with Prostate Cancer in Humans. In: Cancer Surveys on Prostate Cancer - Cell and Molecular Mechanisms in Diagnosis and Treatment. (Isaacs, J.T., Ed.), Cold Spring Harbor Laboratory Press, New York, Vol. 11, pp. 15-24, 1991.
  6. Isaacs, J.T., Morton, R.A., Martikainen, P., and Isaacs, W.B. Growth Factors Affecting Normal and Malignant Prostate Cells. In: Growth Factors in Reproduction. The Serano Symposia, U.S.A. (Schomberg, D.W., Ed.), Springer-Verlag, New York, pp.167-184, 1991.

  7. Borland, R. N., Brendler, C. B. and Isaacs, W. B. Molecular Biology of Bladder Cancer. In: Hematology/Oncology Clinics of North America (Kantoff, P.W., and Scherr, H.I., Eds.), W.B. Saunders, Philadelphia, Vol. 6, pp. 31-40, 1992.

  8. Isaacs, W. B. and Coffey, D. S. Molecular Biology of the Cancer Cell. AUA Update Series, Vol. XI, Lesson 16, pp. 120-125, 1992

  9. Isaacs, W.B. and Coffey, D.S. Understanding DNA Changes in Urological Cancers. In: Oncogenes and Molecular Genetics of Urological Tumors. (Olsson, C.A., Ed.), Churchill Livingstone, New York, pp. 3-14, 1992.

  10. Isaacs, W.B. , Bova, G.S., Brooks, J.D., Ewing, C.M., Morton, R.A., Robinson, J. Genetic alterations in prostate cancer - prognostic implications? In: Prognostic Factors in Urological Cancers (Breul, J., and Hartung, R., Eds.), WZ Verlag, Munich, pp.84-92, 1993.

  11. Isaacs, W.B. , Bova, G.S., Morton, R.A., Bussemakers, M.J.G., and Ewing, C.M. Molecular Biology of Prostate Cancer. In: Seminars in Oncology (Scherr, H., Ed.) Vol. 21, pp. 514-521, 1994.

  12. Isaacs, W.B. , Bova, G.S., Morton, R.A., Bussemakers, M.J.G., and Ewing, C.M. Genetic Alterations in Prostate Cancer. In: Cold Spring Harbor Symposia on Quantitative Biology. Molecular Genetics of Cancer. Cold Spring Harbor Laboratory Press, New York, Vol. LIX, pp. 653-659, 1994.

  13. Isaacs, W.B. , Bova, G.S., Morton, R.A., Bussemakers, M.J.G., Brooks, J.D. and Ewing, C.M.Molecular Biology of Prostate Cancer Progression. In: Cancer Surveys - Preventing Prostate Cancer: Screening versus Chemoprevention (Oliver, R.T.D., Belldegrun, A., and Wrigley, P.F.M., Eds.), Cold Spring Harbor Laboratory Press, New York, Vol. 23, pp. 19-31, 1995.

  14. Isaacs, W.B. Molecular Genetics of Prostate Cancer. In: Cancer Surveys - Genetics and Cancer: A Second Look. Cold Spring Harbor Laboratory Press, New York, Vol. 25, pp. 357-379, 1995.
  15. Isaacs, W.B. Molecular Genetics of Prostate Cancer. In: Comprehensive Textbook of Genitourinary Oncology (Vogelzang, N.J., Scardino, P.T., Shipley, W.U., and Coffey, D.S., Eds),Williams and Wilkins, Baltimore, pp. 579-592, 1995.

  16. Linehan, M., Cordon-Cardo, C., and Isaacs, W.B. Molecular Biology of Genitourinary Cancers. In: Cancer: Principles and Practice of Oncology, Fifth Edition (DeVita, V.T., Hellman, S., and Rosenberg, S.A., Eds.), J.B. Lippincott, Philadelphia, pp.1253-1270, 1997.

  17. Isaacs, W.B. and Isaacs, J.T. Molecular Genetics of Prostate Cancer Progression. In: Principles and Practice of Genitourinary Oncology (Raghavan, D., Scher, H.I., Leibel, S.A., Lange, P., Eds.), Lippincott-Raven, Philadelphia, pp.403-408, 1997.

  18. Isaacs, W.B. and Bova, G.S. Prostate Cancer. In: Metabolic Basis of Inherited Disease, Seventh Edition (Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Eds.), McGraw-Hill, Inc., CD Rom 1997.

  19. Isaacs, W.B. and Bova, G.S. Prostate Cancer. In: The Genetic Basis of Human Cancer (Vogelstein, B., Kinzler, K.W., Eds.), McGraw-Hill, Inc., pp.653-660, 1998.

  20. Isaacs, W.B. and Coffey, D.S. Molecular Genetics of Prostate Cancer. In: Comprehensive Textbook of Genitourinary Oncology, Second Edition (Vogelzang, N.J., Scardino, P.T., Shipley, W.U., Coffey, D.S., Eds.), Lippincott Williams & Wilkins, Philadelphia, pp. 545-552, 2000.

  21. Isaacs, W.B. and Bova, G.S. Prostate Cancer. In: The Metabolic & Molecular Bases of Inherited Disease, Volume I, Eighth Edition (Schriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Eds. and Childs, B., Kinzler, K.W. and Vogelstein, B. Assoc. Eds.) McGraw-Hill, New York, pp. 1125-1134, 2001.

  22. Isaacs, W.B. , Xu, J. and Walsh, P.C. Hereditary Prostate Cancer. In: Prostate Cancer Biology, Genetics, and the New Therapeutics (Chung, L.W.K., Isaacs, W.B. and Simons, J.W., Eds.) Humana Press, Totowa, NJ, pp. 13-28, 2001.

  23. Cockett, A, Cussenot, O., Griffiths, K., Isaacs, W., and Schalken, J. Consultants: Buttyan, R., Prins, G., Steiner, G. Regulation of Prostate Cancer. In: Benign Prostatic Hyperplasia, Fifth Edition (Chatelain, C, Denis, L., Foo, K. T., Khoury, S. and McConnell, J., Editors) Health Publications Ltd., pp.81-106, 2001.

  24. Chang, B., Turner, A., Isaacs, W. and Xu, J. Hereditary Prostate Cancer: The Search for Major Genes and the Role of Genes Involved in Androgen Action. In: Hormones, Genes, and Cancer edited by E. Henderson, Bruce Ponder, and Ronald K. Ross. In Press

    REVIEWS IN JOURNALS
  1. Rinker-Schaeffer, C.W., Isaacs, W.B. and Isaacs, J.T. Molecular and Cellular Markers for Metastatic Prostate Cancer. Cancer Metastasis Rev. 1993 Mar; 12 (1):3 -10.

  2. Jarrard, D.F., Bova, G.S. and Isaacs, W.B. DNA Methylation, Molecular Genetic, and Linkage Studies in Prostate Cancer. Prostate Suppl. 1996; 6:36-44.

  3. Bova, G.S. and Isaacs, W.B. Review of Allelic Loss and Gain in Prostate Cancer. World J. Urol. 1996; 14 (5):338-346.

  4. Morton, R.A., Jr., Ewing, C.M., Watkins, J.J. and Isaacs, W.B. The E-Cadherin Cell-Cell Adhesion Pathway in Urologic Malignancies. World J. Urol. 1995; 13 (6):364-368.

  5. Bookstein, R., Bova, G.S., MacGrogan, D., Levy, A. and Isaacs, W.B. Tumor-Suppressor Genes in Prostatic Oncogenesis: A Positional Approach. British J. Urol. 1997 Mar; Suppl 1:28-36.

  6. Paul, R., Ewing, C.M., Jarrard, D.F. and Isaacs, W.B. The Cadherin Cell-Cell Adhesion Pathway in Prostate Cancer Progression. British J. Urol. 1997 Mar; 79 Suppl. 1:37-43.

  7. Ann W. Hsing, Abraham M. Nomura, William B. Isaacs and Haroutune K. Armenian (Eds.). Prostate Cancer. Epidemiologic Reviews Vol. 23, No. 1, 2001

 


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287